Biocon Subsidiary Now Valued At More Than $4bn After Private Equity Deal
• By David Wallace
Generate a summary of this article
Listen to this article
Biocon has secured the latest in a series of investments in its Biocon Biologics subsidiary, from Abu Dhabi based ADQ. The transaction, worth around $75m, values the biosimilars unit at $4.17bn.
Biocon Biologics has received a further injection of capital • Source: Shutterstock
Biocon has secured a further investment in its Biocon Biologics subsidiary from Abu Dhabi based private equity group ADQ, “one of the region’s largest holding companies.”
The INR5.55bn ($75.7m) investment – which comes in exchange for a 1.80% minority stake in Biocon Biologics – values the...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.